This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2018 Dec;32(6):633-635.

doi: 10.1007/s10557-018-6830-x.

Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

Rosa Ahn¹, Vinay Prasad^{2

3

4}

Affiliations

Affiliations

¹ School of Medicine, Oregon Health & Science University, Portland, OR, USA.
² Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. prasad@ohsu.edu.
³ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁴ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.

PMID: 30232657
DOI: 10.1007/s10557-018-6830-x

Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

Rosa Ahn et al. Cardiovasc Drugs Ther. 2018 Dec.

. 2018 Dec;32(6):633-635.

doi: 10.1007/s10557-018-6830-x.

Authors

Rosa Ahn¹, Vinay Prasad^{2

3

4}

Affiliations

¹ School of Medicine, Oregon Health & Science University, Portland, OR, USA.
² Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. prasad@ohsu.edu.
³ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.
⁴ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA. prasad@ohsu.edu.

PMID: 30232657
DOI: 10.1007/s10557-018-6830-x

Erratum in

Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
Ahn R, Prasad V. Ahn R, et al. Cardiovasc Drugs Ther. 2018 Dec;32(6):637. doi: 10.1007/s10557-018-6834-6. Cardiovasc Drugs Ther. 2018. PMID: 30276760

No abstract available

PubMed Disclaimer

Similar articles

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ. Solomon SD, et al. Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744. Circ Heart Fail. 2016. PMID: 26915374 Clinical Trial.
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
DeVore AD, Hill CL, Thomas L, Sharma PP, Albert NM, Butler J, Patterson JH, Spertus JA, Williams FB, Duffy CI, McCague K, Hernandez AF, Fonarow GC. DeVore AD, et al. Circ Heart Fail. 2018 Sep;11(9):e005400. doi: 10.1161/CIRCHEARTFAILURE.118.005400. Circ Heart Fail. 2018. PMID: 30354360
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS, McMurray JJ. Jhund PS, et al. Heart. 2016 Sep 1;102(17):1342-7. doi: 10.1136/heartjnl-2014-306775. Epub 2016 May 20. Heart. 2016. PMID: 27207980 Free PMC article. Review.
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S, Andries G, Biswas M, Khera S. Yandrapalli S, et al. Vasc Health Risk Manag. 2017 Oct 5;13:369-382. doi: 10.2147/VHRM.S114784. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 29042791 Free PMC article. Review.
Sacubitril/valsartan (Entresto) for heart failure.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9. Med Lett Drugs Ther. 2015. PMID: 26218791 Review. No abstract available.

See all similar articles

Cited by

Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure.
Castro-Torres Y, Katholi RE. Castro-Torres Y, et al. Curr Cardiol Rev. 2020;16(3):202-211. doi: 10.2174/1573403X14666180702151626. Curr Cardiol Rev. 2020. PMID: 32351188 Free PMC article. Review.
Sacubitril/valsartan in Heart Failure and Beyond-From Molecular Mechanisms to Clinical Relevance.
Nikolic M, Srejovic I, Jovic JJ, Sretenovic J, Jeremic J, Cekerevac I, Simovic S, Djokovic D, Muric N, Stojic V, Bolevich S, Bolevich S, Jakovljevic V. Nikolic M, et al. Rev Cardiovasc Med. 2022 Jun 24;23(7):238. doi: 10.31083/j.rcm2307238. eCollection 2022 Jul. Rev Cardiovasc Med. 2022. PMID: 39076908 Free PMC article. Review.
Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials.
Rindone JP, Mellen CK. Rindone JP, et al. Eur J Clin Pharmacol. 2024 Aug;80(8):1113-1120. doi: 10.1007/s00228-024-03686-6. Epub 2024 Apr 10. Eur J Clin Pharmacol. 2024. PMID: 38597935 Review.
Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials.
Rindone JP, Mellen CK, Goldenstein M. Rindone JP, et al. Hosp Pharm. 2024 Jun;59(3):282-287. doi: 10.1177/00185787231212619. Epub 2023 Dec 6. Hosp Pharm. 2024. PMID: 38764991 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal